RNC Capital Management LLC lifted its holdings in Celgene Co. (NASDAQ:CELG) by 0.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,270 shares of the biopharmaceutical company’s stock after buying an additional 45 shares during the period. RNC Capital Management LLC’s holdings in Celgene were worth $684,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the company. Capital Counsel LLC NY boosted its position in shares of Celgene by 0.4% in the second quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock worth $214,000 after buying an additional 6 shares during the period. Fort Pitt Capital Group LLC boosted its position in shares of Celgene by 0.6% in the second quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock worth $250,000 after buying an additional 11 shares during the period. Sowell Financial Services LLC boosted its position in shares of Celgene by 0.5% in the first quarter. Sowell Financial Services LLC now owns 2,454 shares of the biopharmaceutical company’s stock worth $289,000 after buying an additional 13 shares during the period. South Texas Money Management Ltd. boosted its position in shares of Celgene by 0.6% in the first quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical company’s stock worth $305,000 after buying an additional 15 shares during the period. Finally, Flagship Harbor Advisors LLC boosted its position in shares of Celgene by 0.9% in the first quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock worth $253,000 after buying an additional 18 shares during the period. 80.16% of the stock is owned by institutional investors and hedge funds.

Celgene Co. (CELG) opened at $108.24 on Friday. Celgene Co. has a 1-year low of $94.55 and a 1-year high of $147.17. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31. The firm has a market capitalization of $85,849.04, a PE ratio of 17.04, a price-to-earnings-growth ratio of 0.84 and a beta of 1.78.

Celgene (NASDAQ:CELG) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The company had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same period last year, the company earned $1.58 earnings per share. The business’s revenue was up 10.2% compared to the same quarter last year. equities research analysts anticipate that Celgene Co. will post 6.67 EPS for the current year.

Several analysts recently issued reports on the company. Morgan Stanley lowered Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective for the company. in a report on Thursday, October 5th. Royal Bank of Canada reiterated a “buy” rating and set a $173.00 price objective on shares of Celgene in a report on Thursday, October 5th. Robert W. Baird reiterated a “buy” rating and set a $162.00 price objective on shares of Celgene in a report on Thursday, September 21st. Cantor Fitzgerald reiterated a “buy” rating and set a $162.00 price objective on shares of Celgene in a report on Tuesday, September 26th. Finally, Jefferies Group reiterated a “buy” rating and set a $160.00 price objective on shares of Celgene in a report on Friday, September 15th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $136.21.

In other Celgene news, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the transaction, the insider now directly owns 3,925 shares in the company, valued at $564,768.25. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.95% of the stock is owned by company insiders.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.dailypolitical.com/2017/12/15/celgene-co-celg-stake-increased-by-rnc-capital-management-llc.html.

Celgene Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.